摘要
目的探讨大脑多巴胺神经营养因子联合左旋多巴治疗帕金森病的有效性与安全性。方法选取武警浙江省总队杭州医院2014年9月~2016年2月收治的100例帕金森病患者,随机分为单一用药组（n=50）和联合用药组（n=50）。单一用药组使用左旋多巴,联合用药组采用大脑多巴胺神经营养因子联合左旋多巴,分别观察治疗6、12、18 w后患者UPDRS I~Ⅲ评分,血清同型半胱氨酸（Hcy-Serum homocysteine）水平变化及不良反应情况。结果联合用药组治疗6、12、18 w后UPDRSⅠ~Ⅲ评分均显著低于治疗前（P〈0.05）,治疗12、18 w后血清同型半胱氨酸水平均显著低于治疗前（P〈0.05）。联合用药组不良反应发生率为24%,低于单一用药组的84%（P〈0.05）。结论大脑多巴胺神经营养因子联合左旋多巴治疗帕金森病疗效显著,能降低Hcy-水平,不良反应低。
Objective To explore the clinical efficacy and safety of cerebral dopamine neurotrophic factor combined with levodopa in treatment of patients with Parkinson＇s disease. Methods 100 patients from Sep. 2014 to Feb. 2016 in the Armed Police Corps Hospital in Hangzhou, Zhejiang Province were collected and divided into two groups, single drug group （ n = 50） were given levodopa alone, comnination group （ n = 50 ） were given cerebral dopamine neurotrophic factor combined with levodopa. The Unified Parkinson＇s Disease Rating Scale （ UPDRS Ⅰ -Ⅲ） scores, the change of serum homocysteine levels and adverse reaction were observed. Results UPDRS Ⅰ -Ⅲ score of patients in conbimation group were significantly lower than pre-treatment（ P 〈 0. 05 ）, the levels of serum homocysteine were significantly lower than pre-treatment （ P 〈 0. 05 ）. The adverse reaction rate of conbimation group was 24% , lower than that of single drug group （ P 〈 0. 05 ）. Conclusion Cerebral dopamine neurotrophic factor combined with levodopa in treatment of patients has better efficacy and higher safety.
出处
《中国生化药物杂志》
CAS
2016年第5期174-176,共3页
Chinese Journal of Biochemical Pharmaceutics
基金
浙江省自然科学基金(LQ14H090004)
